The last few months, ever since funding/ partner news started in the US, price was kept below 15.5 cents, allowing for accumulation waves, only to see price pushed back each time. That TH you speak of could well include funding/ partnering news, positive toxicity and tolerability data being the triggering milestone.
One possible scenario is that the upcoming partner has a licence deal for CNS, stomach, daiphram and kidney programs, whereas PYC OZ maintains leadership of the ocular pipeline. That would enable the broad expansion of pipeline work management repeatedly referred to and fell so silent on in latest quarterly, only concentrating on the lead ocular program.
all IMO
PYC Price at posting:
14.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)